Generic Tuzistra XR Availability
Last updated on Apr 10, 2025.
Tuzistra XR is a brand name of chlorpheniramine/codeine, approved by the FDA in the following formulation(s):
TUZISTRA XR (chlorpheniramine polistirex; codeine polistirex - suspension, extended release;oral)
-
Manufacturer: TRIS PHARMA INC
Approval date: April 30, 2015
Strength(s): EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tuzistra XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Modified release formulations containing drug-ion exchange resin complexes
Patent 8,062,667
Issued: November 22, 2011
Inventor(s): Mehta; Ketan et al.
Assignee(s): Tris Pharma, Inc. (Monmouth Junction, NJ)A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.
Patent expiration dates:
- March 29, 2029✓
- March 29, 2029
-
Modified release formulations containing drug-ion exchange resin complexes
Patent 8,790,700
Issued: July 29, 2014
Inventor(s): Mehta Ketan & Tu Yu-Hsing
Assignee(s): TRIS Pharma, Inc.An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making the coated complex and the liquid suspension are described.
Patent expiration dates:
- March 15, 2027✓
- March 15, 2027
More about Tuzistra XR (chlorpheniramine / codeine)
- Tuzistra XR consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: upper respiratory combinations
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.